AXSM · Axsome Therapeutics, Inc.
$145.04
-7.07% last session
End-of-day data · close of 2026-10-23
Market cap
$8B
Enterprise value
$8B
Trailing P/E
—
Forward P/E
39.3
Dividend yield
0.0%
Beta
0.85
Avg volume
1M
Employees
1K
Daily Change %
-7.07%
5 Days Change
-0.68%
10 Days Change
-0.16%
30 Days Change
-19.32%
60 Days Change
-24.02%
Month to Day Change
-14.28%
Year to Day Change
-14.55%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — AXSM
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-26
Latest call per bank · past 12 months
RBC Capital
Outperform$295
+103.4% vs priceDeutsche Bank
Buy$267
+84.1% vs priceMorgan Stanley
Equal-Weight$247
+70.3% vs priceWells Fargo
Overweight$256
+76.5% vs priceJefferies
Buy$275
+89.6% vs priceUBS
Buy$259
+78.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-26 | Piper Sandler | Maintains | Overweight | $258 → $238 |
| 2026-10-08 | RBC Capital | Maintains | Outperform | $297 → $295 |
| 2026-09-29 | Deutsche Bank | Maintains | Buy | $280 → $267 |
| 2026-09-25 | Morgan Stanley | Maintains | Equal-Weight | $251 → $247 |
| 2026-09-23 | Truist Securities | Maintains | Buy | $200 → $285 |
| 2026-09-18 | Piper Sandler | Reiterates | Overweight | $258 |
| 2026-08-31 | HC Wainwright & Co. | Reiterates | Buy | $290 |
| 2026-08-12 | Mizuho | Maintains | Outperform | $306 → $316 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- bullish: RSI (14): RSI is 22 — oversold territory; selling pressure looks stretched.
- bearish: Price vs 50-day MA: Trading 24.4% below the 50-day MA ($191.84).
- bearish: Price vs 200-day MA: Trading 27.5% below the 200-day MA ($200.06).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.67) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($127.06) and high ($255.17).
AXSM Price Chart
Loading chart for AXSM…
Fundamentals
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.